10,000 Shares in Tempus AI, Inc. $TEM Purchased by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC bought a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $452,000.

Other large investors have also modified their holdings of the company. Royal Bank of Canada boosted its stake in shares of Tempus AI by 201.2% during the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after purchasing an additional 17,359 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Tempus AI in the 1st quarter valued at $116,000. Prudential Financial Inc. bought a new position in shares of Tempus AI in the 2nd quarter worth $276,000. Russell Investments Group Ltd. lifted its stake in shares of Tempus AI by 21.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after purchasing an additional 1,146 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Tempus AI by 2,926.6% during the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after purchasing an additional 204,629 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Price Performance

Tempus AI stock opened at $52.47 on Monday. The business’s 50-day simple moving average is $51.60 and its two-hundred day simple moving average is $54.00. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The company has a market cap of $9.42 billion, a PE ratio of -30.51 and a beta of 3.46. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period last year, the business posted ($0.24) earnings per share. Equities analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current year.

Insider Buying and Selling

In other Tempus AI news, CEO Ryan Fukushima sold 33,284 shares of the stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $57.39, for a total transaction of $1,910,168.76. Following the sale, the chief executive officer directly owned 167,763 shares of the company’s stock, valued at approximately $9,627,918.57. This trade represents a 16.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan M. Bartolucci sold 4,116 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $181,392.12. Following the sale, the chief accounting officer directly owned 74,041 shares in the company, valued at approximately $3,262,986.87. This trade represents a 5.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 616,043 shares of company stock valued at $31,748,593 in the last 90 days. 24.26% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have issued reports on TEM. Wall Street Zen lowered Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Guggenheim raised their price target on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday. Jefferies Financial Group initiated coverage on shares of Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Finally, BTIG Research reiterated a “buy” rating and set a $80.00 price objective on shares of Tempus AI in a report on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $68.92.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.